Chardan Capital Have $35.0 Target On Audentes Therapeutics (BOLD).

June 27, 2018 - By Maria Fierro

What Price Target Has Chardan Capital Given Audentes Therapeutics (BOLD)

Chardan Capital’s Equities researchers have $35.0 PT which indicates upside potential of 31.63 % on Audentes Therapeutics (BOLD). Chardan Capital also has started coverage of BOLD stock on Tuesday, 26 June.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Ratings Coverage

In total 5 analysts cover Audentes Therapeutics (BOLD). “Buy” rating has 3, “Sell” are 0, while 2 are “Hold”. 60% are bullish. 10 are the (BOLD)’s analyst reports since January 4, 2018 according to StockzIntelligence Inc. On Wednesday, May 2 the rating was maintained by H.C. Wainwright with “Buy”. In Thursday, May 17 report H.C. Wainwright maintained the stock with “Buy” rating. On Friday, March 9 the stock of Audentes Therapeutics, Inc. (NASDAQ:BOLD) earned “Buy” rating by H.C. Wainwright. The company rating was initiated by Mizuho on Monday, February 12. In Thursday, January 4 report William Blair maintained the stock with “Buy” rating. In Thursday, January 11 report H.C. Wainwright maintained it with “Buy” rating and $37.0 target. The company rating was maintained by H.C. Wainwright on Wednesday, February 7. On Thursday, January 4 the stock has “Buy” rating by H.C. Wainwright.

BOLD hit $40.32 during the last trading session after $0.7 change.Audentes Therapeutics, Inc. is uptrending after having risen 142.34% since June 27, 2017. BOLD has 744,178 volume or 65.41% up from normal. The stock outperformed the S&P500 by 129.77%.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) is anticipated to reveal earnings on August, 9., as reported by RTT. Analysts forecast 11.49 % diference or $-0.77 from the $-0.87 EPS from 2017. Analysts at Wall Street see Audentes Therapeutics, Inc.’s 4.05 % negative EPS growth compared to $-0.74 earnings per share for last quarter.

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects.The firm is worth $1.48 billion. The firm is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy ; AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.Last it reported negative earnings. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar.

More recent Audentes Therapeutics, Inc. (NASDAQ:BOLD) news were announced by Globenewswire.com, Benzinga.com and Benzinga.com. The first one has “Market Trends Toward New Normal in Audentes Therapeutics, Aqua Metals, BT Group, Mid-America Apartment …” as a title and was announced on May 31, 2018. The next is “Benzinga’s Top Upgrades, Downgrades For June 26, 2018” on June 26, 2018. And last was announced on June 21, 2018, called “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street”.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.